Cargando…

Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma

AIM: Intensity-modulated radiotherapy (IMRT) is a widely accepted therapy for nasopharyngeal carcinoma (NPC), but it inevitably brings out radiation-related complications and seriously affects the quality of life (QoL). Endoscopic nasopharyngectomy (ENPG) has been successfully conducted in locally r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Benjian, Li, Yiliang, Weng, Jingjin, Huang, Bo, Ban, Molu, Lan, Guiping, Lu, Yu, Luo, Jianhui, Qu, Shenhong, Si, Yongfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085368/
https://www.ncbi.nlm.nih.gov/pubmed/33896244
http://dx.doi.org/10.1177/15330338211011975
_version_ 1783686323965526016
author Zhang, Benjian
Li, Yiliang
Weng, Jingjin
Huang, Bo
Ban, Molu
Lan, Guiping
Lu, Yu
Luo, Jianhui
Qu, Shenhong
Si, Yongfeng
author_facet Zhang, Benjian
Li, Yiliang
Weng, Jingjin
Huang, Bo
Ban, Molu
Lan, Guiping
Lu, Yu
Luo, Jianhui
Qu, Shenhong
Si, Yongfeng
author_sort Zhang, Benjian
collection PubMed
description AIM: Intensity-modulated radiotherapy (IMRT) is a widely accepted therapy for nasopharyngeal carcinoma (NPC), but it inevitably brings out radiation-related complications and seriously affects the quality of life (QoL). Endoscopic nasopharyngectomy (ENPG) has been successfully conducted in locally recurred NPC, but few studies evaluated its application in early NPC. This study aims to assess the feasibility and safety of ENPG combined with low-dose radiotherapy (LDRT) in T1-2 NPC. PATIENTS AND METHODS: We recruited 37 newly diagnosed localized T1-2 NPC patients who voluntarily accepted ENPG +LDRT from June 2013 to September 2016. Meanwhile, the data of 132 T1-2 NPC patients treated with IMRT were collected and used as control group. The survival outcomes, QoL score and late RT-related sequelaes were compared between the 2 groups. RESULTS: After a median follow-up of 54 months, only 1 patient in ENPG+LDRT group died along with hepatic metastases. The 5-year overall survival, distant metastasis-free survival, local relapse-free survival and regional relapse-free survival in ENPG+LDRT group were 97.3%, 97.3%, 100% and 100%, which were not statistically different from the control group (97.7%, 90.2%, 95. 5%, 97.0%, respectively, all P > 0.05). In comparison with IMRT group, ENPG+LDRT exhibited better QoL and less rate of late RT-related sequlaes including hearing loss (53.8% vs 27.0%, P = 0.005), xerostomia (46.2% vs 24.3%, P = 0.023) and dysphagia (25.8% vs 8.1%, P = 0.024). CONCLUSIONS: ENPG+LDRT provided satisfactory survival outcomes, and improved the QoL and reduced the incidence of sequelae for T1-2 NPC patients.
format Online
Article
Text
id pubmed-8085368
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80853682021-05-13 Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma Zhang, Benjian Li, Yiliang Weng, Jingjin Huang, Bo Ban, Molu Lan, Guiping Lu, Yu Luo, Jianhui Qu, Shenhong Si, Yongfeng Technol Cancer Res Treat Original Article AIM: Intensity-modulated radiotherapy (IMRT) is a widely accepted therapy for nasopharyngeal carcinoma (NPC), but it inevitably brings out radiation-related complications and seriously affects the quality of life (QoL). Endoscopic nasopharyngectomy (ENPG) has been successfully conducted in locally recurred NPC, but few studies evaluated its application in early NPC. This study aims to assess the feasibility and safety of ENPG combined with low-dose radiotherapy (LDRT) in T1-2 NPC. PATIENTS AND METHODS: We recruited 37 newly diagnosed localized T1-2 NPC patients who voluntarily accepted ENPG +LDRT from June 2013 to September 2016. Meanwhile, the data of 132 T1-2 NPC patients treated with IMRT were collected and used as control group. The survival outcomes, QoL score and late RT-related sequelaes were compared between the 2 groups. RESULTS: After a median follow-up of 54 months, only 1 patient in ENPG+LDRT group died along with hepatic metastases. The 5-year overall survival, distant metastasis-free survival, local relapse-free survival and regional relapse-free survival in ENPG+LDRT group were 97.3%, 97.3%, 100% and 100%, which were not statistically different from the control group (97.7%, 90.2%, 95. 5%, 97.0%, respectively, all P > 0.05). In comparison with IMRT group, ENPG+LDRT exhibited better QoL and less rate of late RT-related sequlaes including hearing loss (53.8% vs 27.0%, P = 0.005), xerostomia (46.2% vs 24.3%, P = 0.023) and dysphagia (25.8% vs 8.1%, P = 0.024). CONCLUSIONS: ENPG+LDRT provided satisfactory survival outcomes, and improved the QoL and reduced the incidence of sequelae for T1-2 NPC patients. SAGE Publications 2021-04-26 /pmc/articles/PMC8085368/ /pubmed/33896244 http://dx.doi.org/10.1177/15330338211011975 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Zhang, Benjian
Li, Yiliang
Weng, Jingjin
Huang, Bo
Ban, Molu
Lan, Guiping
Lu, Yu
Luo, Jianhui
Qu, Shenhong
Si, Yongfeng
Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma
title Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma
title_full Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma
title_fullStr Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma
title_full_unstemmed Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma
title_short Efficacy and Safety of Endoscopic Nasopharyngectomy Combined With Low-Dose Radiotherapy for Primary T1-2 Nasopharyngeal Carcinoma
title_sort efficacy and safety of endoscopic nasopharyngectomy combined with low-dose radiotherapy for primary t1-2 nasopharyngeal carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085368/
https://www.ncbi.nlm.nih.gov/pubmed/33896244
http://dx.doi.org/10.1177/15330338211011975
work_keys_str_mv AT zhangbenjian efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT liyiliang efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT wengjingjin efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT huangbo efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT banmolu efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT languiping efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT luyu efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT luojianhui efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT qushenhong efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma
AT siyongfeng efficacyandsafetyofendoscopicnasopharyngectomycombinedwithlowdoseradiotherapyforprimaryt12nasopharyngealcarcinoma